《新股表現》翰森製藥(03692.HK)半日收17.96元高上市價26%
翰森製藥(03692.HK)暗盤收16.02元,高上市價逾12%;該股首掛高開14%報16.3元,最多漲31%高見18.7元遇壓,半日收17.96元,較上市價14.26元,高26%,半日成交9,659萬股,涉資1.63億元。
翰森是為數不多以研發為主導的中國製藥公司之一,其於中樞神經系統疾病、抗腫瘤、抗感染及糖尿病方面擁有廣泛、多元化及領先的藥物組合,公司還專注於消化道及心血管治療領域。是次來港上市共發5.51億股,並已引入高瓴資本、博裕資本、GIC、匯橋資本、奧博資本、上海醫藥(02607.HK)及維梧資本等九名基石投資者,合共認購1.89億股(禁售股半年);7%公開發售獲近11倍超購,認購一手中籤率60%,股份以招股範圍(13.06-14.26元)上限定價,料集資淨額76.4億元,主要用於研發、擴充研發團隊及在研發技術投資、用作生產體系、建設新生產線、升級現有生產設施並提高其自動化水平、以及銷售和學術推廣以配合新產品上市等。上市聯席保薦人分別為大摩及花旗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.